Tilray Inc (TLRY)
$18.20
0.35 (1.89%)
TLRY Stock Quote Delayed 15 Minutes
Previous Close
$18.20
Market Cap
-
PE Ratio
-
EPS
-
Volume (Avg. Vol.)
1.24M
Day's Range
18.07 - 18.88
52-Week Range
18.00 - 106.00
Dividend & Yield
N/A (N/A)
TLRY Stock Predictions, Articles, and Tilray Inc News
With Profitability Nowhere in Sight, Tilray Stock Has Further to Fall
Tilray stock tumbles as investors demand profitability. Tilray, like other cannabis stocks, is stuck in a death spiral as long as the copmany can't produce profits.
Plunging Tilray Stock Shows Just How Much Sentiment Has Changed
Tilray stock keeps falling and now is nearing its IPO price. Trading in TLRY stock shows how much faith investors have lost in pot stocks.
Has Tilray Stock Finally Hit Rock-Bottom?
It’s been absolutely grueling for Tilray stock. It seems like nothing can help shares. But interestingly enough, this may be setting up a good entry point for TLRY.
Tilray Stock Hammered as Investors Turn on Cannabis Producers
Revised earnings guidance for Hexo spooked the market and hit cannabis stocks, with Tilray stock closing down 13.5% on Thursday.
These Troubles Won’t Last for Tilray Stock, but They’re Not Fading Fast
Tilray stock's 52-week high is just under $179. On Friday, Oct. 4, the shares barely closed above $24. The outlook for Tilray and some of its marijuana rivals will improve at some point. Knowing when that point will arrive, well, that's a different ballgame. Over the near-term, things are problematic for Tilray stock because losses are accelerating. Over the past month, the shares are lower by 25% and the loss of the past quarter is almost double that.
Should Investors Have More Patience with Tilray Stock?
Opportunities abound for Tilray stock but the cannabis infrastructure still needs to be built out, along with more favorable legalization momentum. For now, TLRY is interesting, but it will require patience from investors.
Pretty Much Any Pot Play Makes More Sense Than Buying Tilray Stock
The company has several catalysts in play, but nothing unique compared to what other cannabis companies are doing. I remain on the fence with pot stocks in general. But if I were entering a position today, I would choose something like Hexo or Aphria to place my bet on the legalized marijuana story. I suggest you do the same. Look elsewhere for a pot play, but steer clear of TLRY stock.
Buy Tilray Stock Regardless of Whether the SAFE Act Becomes Law
The SAFE Banking Act might not pass the Senate, but that doesn't mean you can't buy TLRY stock.
The Tables Could Soon Turn Back in Favor of Tilray Stock
Tilray stock has been beaten to a pulp, like most other pot stocks. But, there's a nuance here that could readily reignite TLRY shares.
Wait for the Post-Earnings Dust to Settle Before Buying ACB Stock
This has been a tough year for cannabis stocks, and ACB stock continues to slump two weeks after it was hammered by Q4 earnings.
There’s Really No Point in Buying Tilray Stock Before a Catalyst Emerges
As Tilray CEO Brendan Kennedy stated in its Q2 2019 press release, the company nearly doubled its adult-use revenue in the quarter.
CGC Stock Looks Like a Buy on the Dip as Stock Falters on Vape Worries
Cannabis stocks are in a bear phase and it is taking CGC stock down with it. Beyond next year, profits are around the corner.
Why Investors Should Stay Away From Tilray Stock
The downtrend of Tilray stock has serious momentum, and it's best to avoid stepping in the way of this downward pressure on TLRY for now.
Should You Believe the Long-Term Narrative for Tilray Stock?
Once a high-flying cannabis player, Tilray stock has floundered along with the rest of the industry. But having recently found a bottom, speculators may be tempted to bet on TLRY’s long shot but viable narratives.
Is Tilray Stock’s Crushing Bear Market Finally Over?
Will Tilray's growth strategy lead to a new bull market in the stock? Or is it time to sell Tilray stock on its recent bounce?
Is Aurora Cannabis Stock a Buy Despite a Revenue Miss?
Throughout this year, marijuana-related investments like Aurora Cannabis stock took a massive beating. Still, markets work in cycles and with ACB not dropping to new lows, it suggests a possible turnaround is coming with the right catalyst.
Unfortunately, Aphria Stock Suffers from Guilt by Association
Stepping into Aphria stock now is a little bit like catching a falling knife. Just wait for it to hit the floor.
Keep an Eye on Canopy Growth Stock, but Don’t Buy It Just Yet
Shares of Canopy Growth stock have been struggling immensely over the last few months. However, CGC has some new momentum.
Navellier Ratings
Powered by Portfolio GraderTotal Grade
F
